Co-Co Licenses. In the event that through the JGC the Parties identify Patents, Know-How or Materials of a Third Party that are necessary to Develop and Commercialize Elected Candidate and Licensed Product worldwide, upon JGC recommendation, one or the other Party (or both) will use commercially reasonable efforts to obtain a license or other rights to such Patents, Know-How or Materials for use in connection with the performance of such Development and Commercialization (“Co-Co In-Licenses”). Prior to entering into any Co-Co In-License, the contracting Party will provide a draft copy to the other Party and the other Party will have the right to review and provide comments to such proposed Co-Co In-License. Neither Party will enter into a Co-Co In-License without the prior approval of the JGC, provided that [[Celgene Corp:Organization]] will be free to enter into any Co-Co In-License for ROW Administration notwithstanding this Section 8.1. If a Party enters into any Co-Co In-Licenses during the CCPS Agreement Term, [Appendix E] hereto will be updated accordingly to include such Co-Co In-Licenses.

SYNGAP1 Co-Co Products. The Parties will jointly develop a global publication strategy for the [[Unknown Identifier]] Co-Co Products, including a strategy for the publication of data generated under this Agreement from the conduct of Clinical Trials for [[Unknown Identifier]] Co-Co Products.

“Co-Issuers”: The Issuer and the Co-Issuer.

the institution by the shareholders of the Issuer or the members of the Co-Issuer of Proceedings to have the Issuer or the Co-Issuer, as the case may be, adjudicated as bankrupt or insolvent, or the consent by the shareholders of the Issuer or the members of the Co-Issuer to the institution of bankruptcy or insolvency Proceedings against the Issuer or the Co-Issuer, as the case may be, or the filing by the Issuer or the Co-Issuer of a petition or answer or consent seeking reorganization or relief under the Bankruptcy Law or any other similar applicable law, or the consent by the Issuer or the Co-Issuer to the filing of any such petition or to the appointment in a Proceeding of a receiver, liquidator, assignee, trustee or sequestrator (or other similar official) of the Issuer or the Co-Issuer or of any substantial part of its property, respectively, or the making by the Issuer or the Co-Issuer of an assignment for the benefit of creditors, or the admission by the Issuer or the Co-Issuer in writing of its inability to pay its debts generally as they become due, or the taking of any action by the Issuer or the Co-Issuer in furtherance of any such action; or

“Board of Directors”: With respect to the Issuer, the board of directors of the Issuer appointed pursuant to the current articles of association of the Issuer, and with respect to the Co-Issuer, the managers of the Co-Issuer duly appointed by the members of the Co-Issuer.

“Issuer Order” and “Issuer Request”: A written order or request (which may be a standing order or request) dated and signed in the name of the Issuer or the Co-Issuer or by a Responsible Officer of the Issuer or the Co-Issuer or by the Collateral Manager by a Responsible Officer thereof, on behalf of the Issuer or the Co-Issuer.

“Co-Issuer”: JMP Credit Advisors CLO III(R) LLC, until a successor Person shall have become the Co-Issuer pursuant to the applicable provisions of this Indenture, and thereafter “Co-Issuer” shall mean such successor Person.

The Issuer shall, subject to the Priority of Payments, reimburse the Co-Issuer for any amounts paid by the Co-Issuer pursuant to the terms of the Notes or this Indenture. The Co-Issuer shall not reimburse the Issuer for any amounts paid by the Issuer pursuant to the terms of the Notes or this Indenture.

Co-operation. Licensee shall (at no cost to Bioeq if this Agreement is terminated by Bioeq pursuant to [Sections 15.2.1, 15.2.2, 15.2.3, 15.2.4, 15.2.8 or 15.2.9]9]9]9], or by Licensee pursuant to [Section 15.2.5], or at Bioeq’s cost and expense if this Agreement is terminated by Licensee pursuant to [Sections 15.2.1, 15.2.6, 15.2.7 or 15.2.8]8]8], as applicable) use Commercially Reasonable Efforts to cooperate with Bioeq or its designee, and provide ​ reasonable assistance and support, to ​ Bioeq or its designee to take over the Commercialization of the Licensed Products in the Field in the Territory ​ following the effective date of such termination, including by # using Commercially Reasonable Efforts to provide ​, # disclosing and assigning (to the extent permitted under the relevant agreement) to Bioeq Licensee’s existing agreements relating solely to the Commercialization of the Licensed Product in the Territory, including with ​, to the extent legally possible (​) and # transferring Licensed Product-specific marketing materials, including ​. With respect to any such information, materials or agreements provided to Bioeq pursuant to this [Section 15.3.3], Licensee may redact information relating to other products which are not Licensed Products as well as proprietary information of the relevant Third Party from such information, materials, or agreements prior to providing the same to Bioeq. Additionally, to the extent Licensee has agreements relating to the Commercialization of both the Licensed Products and other products in the Territory with wholesalers, distributors, pharmacies, hospitals, health insurances and other relevant parties, upon request from Bioeq, Licensee shall introduce Bioeq to such parties and ​.

Co-Employment. Employer and Employee acknowledge that Employer has or may enter into a contract with a third party to provide human resource services to Employer and that in connection with such contract Employee may become a “co-employee” of Employer and such third party, and that, among other things, Employee may receive his compensation indirectly from Employer from amounts paid by Employer to such third party for the purpose of compensating Employee. Employer and Employee agree that notwithstanding such arrangement, it is the intent of Employer and Employee that the duties and obligations of each Party described in this Agreement shall continue to be owed to the other Party as if Employee was not in a co- employment relationship with a third party.